Introduction
For years, real-world evidence sat at the edges of regulatory work: useful for post-market safety surveillance, occasionally cited in a label expansion, rarely central to an approval decision. That has been changing. FDA has published a real-world evidence framework and multiple related guidance documents describing how data from electronic health records, claims databases, registries, and other non-trial sources can support regulatory decisions, including in some cases as evidence for effectiveness. EMA has pursued parallel work through its Big Data and DARWIN EU initiatives, building infrastructure for regulators to query real-world data directly. None of this replaces randomized controlled trials as the backbone of drug and device evidence, and hedging that point matters, but it does mean real-world evidence has moved from a supporting exhibit to a more structural part of many submissions and post-approval commitments. That shift is creating regulatory affairs work that did not exist in its current form a decade ago, and it is worth understanding if you are shaping your career or evaluating where to specialize next.
Why This Is a Regulatory Affairs Problem, Not Just a Data Science One
Real-world evidence work is often described as a data science or epidemiology function, and much of the underlying analysis is exactly that. But turning a real-world data analysis into something a regulatory submission can actually use requires regulatory affairs judgment that data scientists are not trained to provide on their own. Someone has to determine whether a proposed real-world evidence source and study design would plausibly satisfy a specific regulatory question, translate agency guidance into study protocols the data team can execute against, and manage the ongoing dialogue with FDA or EMA about whether the evidence generation plan is fit for purpose before the data collection even starts. That is regulatory strategy work wearing a real-world evidence label, and it increasingly requires people who are fluent in both the regulatory framework and the practical limitations of observational data.
This is also why the work tends to land with people who already have regulatory affairs experience rather than being handed entirely to a data science or biostatistics team. An epidemiologist can build a technically sound observational study; whether that study design will actually satisfy a specific FDA or EMA information request, and how to frame it in a submission so a reviewer can evaluate it efficiently, is a judgment call that comes from regulatory experience. Companies that get this wrong tend to either exclude regulatory affairs from real-world evidence planning until too late, producing evidence packages that do not map cleanly onto what the agency asked for, or exclude data science expertise from regulatory planning, producing evidence generation plans that sound reasonable on paper but are not methodologically defensible. The roles that work well sit deliberately at that intersection.
Where the Work Shows Up in Practice
Real-world evidence regulatory work tends to cluster in a few recurring situations. Post-approval commitments and label expansions are the most established use case: a sponsor commits to generating real-world evidence as a condition of approval or to support expanding an indication, and someone has to manage that commitment through to a regulatory filing. Rare disease and orphan drug programs, where randomized trials are difficult to power adequately, increasingly lean on natural history studies and external control arms built from real-world data, requiring regulatory professionals who understand how to justify that approach to an agency. Medical device and diagnostics companies use real-world data for post-market surveillance obligations under frameworks like MDR, which explicitly requires ongoing clinical evidence generation after a device reaches market. And safety signal evaluation increasingly draws on real-world data sources alongside traditional pharmacovigilance databases.
What the Role Actually Looks Like
Titles vary, and "real-world evidence" is rarely the entire job description on its own; more often it shows up as a specialization within a broader regulatory strategy, regulatory affairs, or evidence generation role. The work typically involves reviewing proposed real-world evidence study designs for regulatory adequacy before they go to an agency, drafting or reviewing the regulatory sections of evidence generation plans, preparing briefing documents and meeting requests when a sponsor wants agency feedback on a real-world evidence approach, and staying current on a body of guidance that is still actively evolving rather than settled. It is a role that rewards people who are comfortable holding two things at once: genuine scientific literacy about the strengths and limits of observational data, and the regulatory affairs instinct for what an agency reviewer will actually accept.
Skills Worth Building
If this niche interests you, a few things are worth developing deliberately. Read the FDA real-world evidence framework and related guidance documents directly rather than secondhand summaries; the specific language agencies use about fit-for-purpose data and study design shows up again in submission strategy conversations. Build enough fluency in epidemiological study design, cohort studies, external control arms, propensity score matching, to have an informed conversation with a biostatistician or epidemiologist, even if you are not running the analysis yourself. Follow how EMA's DARWIN EU network is being used in practice, since European regulators are building direct query capability into real-world data that will change how these conversations happen going forward. And if you already have RAC certification or similar credentials, look at whether your organization or professional societies like RAPS or DIA offer real-world evidence-specific training, since dedicated coursework in this area is younger and less standardized than in core regulatory affairs.
Where the Caution Signs Are
It is worth being honest about the limits of this trend rather than overselling it. Real-world evidence still plays a supporting role in the large majority of approvals, and agencies have been explicit that it is not a substitute for well-designed trials where trials are feasible. Guidance in this area continues to evolve, which means the regulatory expectations you learn today may shift meaningfully within a few years, and professionals in this niche need to stay current rather than treating any single framework as fixed. It is also worth noting that real-world evidence carries inherent methodological limitations that trial data does not, particularly around confounding and data quality, and part of the regulatory affairs judgment in this space is knowing when those limitations make a real-world evidence approach unsuitable for a given regulatory question, not just how to build the strongest possible case for using it. And because this is still an emerging specialization, formal hiring categories and job titles are less standardized than in established regulatory functions, so candidates should expect to describe their real-world evidence experience clearly in a resume and interview rather than relying on a title to convey it.
How to Signal This Experience if You Already Have It
If you have already touched real-world evidence work, even as a smaller part of a broader regulatory role, it is worth naming specifically on a resume rather than folding it into general submission experience. Describe the actual contribution: reviewing a real-world evidence study design for regulatory adequacy, drafting sections of an evidence generation plan, preparing a briefing document for an agency meeting on a real-world data approach, or managing a post-approval commitment through to filing. Hiring managers in this space are usually looking for concrete examples of exactly this kind of work rather than a title, since the titles themselves are still inconsistent across companies. If you have not yet had the chance to work on a real-world evidence project directly, volunteering to support one, even in a coordinating capacity, is a reasonable way to start building the specific experience this niche rewards.
How This Fits Into a Broader Regulatory Career
It is worth treating real-world evidence as a specialization layered onto solid regulatory affairs fundamentals rather than a separate career track. The professionals doing this work well are, first, competent regulatory strategists who understand submission requirements, agency interaction norms, and how evidence packages get assembled, and second, conversant enough in real-world data methods to evaluate whether a proposed approach will hold up. That ordering matters: a strong regulatory affairs foundation transfers into this niche far more easily than real-world data expertise transfers into general regulatory affairs competence. If you are earlier in your career, prioritize building core regulatory affairs skills first and treat real-world evidence exposure as a differentiator you layer in once those fundamentals are solid, rather than trying to specialize before you have the base to specialize from.
Conclusion
Real-world evidence is not replacing traditional regulatory affairs work, but it is expanding what the job requires from a meaningful subset of the field, particularly in rare disease, post-approval commitments, and device post-market surveillance. For regulatory professionals willing to build real fluency in both the data science and the regulatory strategy sides of this work, it is a defensible way to differentiate a career, and the demand for people who can do both competently is likely to keep growing as agencies build more infrastructure to use this evidence directly. The professionals who will benefit most are not necessarily the ones who chase the newest terminology, but the ones who quietly build both halves of the skill set while the field is still defining what the standard career path looks like.